New follow-up research on baricitinib for type 1 diabetes addresses a crucial question: what happens after the drug is stopped? The original BANDIT trial showed that 48 weeks of oral baricitinib helped preserve beta-cell function in people with recently diagnosed type 1 diabetes. However, new follow-up research examines participants through …
Read More »The Honeymoon Phase Won’t Last Forever: Are We Doing Enough to Preserve Beta Cells?
Receiving a diagnosis of type 1 diabetes can feel overwhelming. Yet for many adults, the weeks or months that follow bring an unexpected twist. Blood glucose levels often become easier to control, insulin needs decrease, and some people wonder if their diabetes is actually improving. This temporary period is known …
Read More »The Return of C-Peptide: Why This Old Biomarker Is Finding New Clinical Uses
For many years, C-peptide testing was viewed as a simple tool to distinguish type 1 diabetes from type 2 diabetes. However, the story has changed. As researchers gain a better understanding of pancreatic beta-cell function, C-peptide testing in diabetes has become much more valuable than a diagnostic aid alone. Today, …
Read More »Diabetes Without Clear Etiology: When Patients Don’t Fit Type 1 or Type 2
What happens when a patient walks into your clinic and their diabetes simply doesn’t fit the usual mold? In many cases, clinicians rely on well-established categories like Type 1 or Type 2 diabetes. However, diagnosing atypical forms of diabetes is becoming increasingly important as more patients present with mixed or …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.